Investors Purchase High Volume of Put Options on Valeant Pharmaceuticals Intl (VRX)
Valeant Pharmaceuticals Intl (NYSE:VRX) was the recipient of unusually large options trading on Thursday. Stock traders acquired 12,569 put options on the company, Stock Ratings Network reports. This is an increase of approximately 390% compared to the typical volume of 2,567 put options.
Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of Valeant Pharmaceuticals Intl from an “outperform” rating to an “underperform” rating in a research note on Wednesday, August 6th. They now have a $101.00 price target on the stock. Separately, analysts at Susquehanna cut their price target on shares of Valeant Pharmaceuticals Intl to $160.00 in a research note on Friday, August 1st. Finally, analysts at Piper Jaffray cut their price target on shares of Valeant Pharmaceuticals Intl from $151.00 to $135.00 in a research note on Friday, August 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $148.00.
Valeant Pharmaceuticals Intl (NYSE:VRX) traded up 1.71% during mid-day trading on Thursday, hitting $111.04. The stock had a trading volume of 4,394,741 shares. Valeant Pharmaceuticals Intl has a 52 week low of $95.28 and a 52 week high of $153.10. The stock has a 50-day moving average of $120.1 and a 200-day moving average of $129.4. The company’s market cap is $37.244 billion.
Valeant Pharmaceuticals Intl (NYSE:VRX) last issued its quarterly earnings data on Thursday, July 31st. The company reported $1.91 earnings per share for the quarter, meeting the analysts’ consensus estimate of $1.91. The company had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter last year, the company posted $1.34 earnings per share. Valeant Pharmaceuticals Intl’s revenue was up 86.2% compared to the same quarter last year. On average, analysts predict that Valeant Pharmaceuticals Intl will post $7.99 earnings per share for the current fiscal year.
Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.